A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and Manufacturers of America that incorrectly blame hospitals for the rising price of drugs. The latest installment of the Campaign for Sustainable Rx Pricing’s “Second Opinion” series highlights how hospitals are subject to fixed reimbursements for the vast majority of care they provide, and the “true driver behind the rising costs is PhRMA’s willingness to do anything for an extra dollar, even if it means forcing patients to choose between paying for the medicines they need and their daily life necessities.” CSRxP, of which the AHA is a founding member, said it will continue to fact check PhRMA’s false claims and move forward with patient-focused solutions to increase transparency, promote competition and ensure a drug’s price is based on how well it works for patients. 
 

Related News Articles

Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…